Scancell (LON:SCLP) Hits New 52-Week Low – Here’s Why

Scancell Holdings plc (LON:SCLPGet Free Report)’s stock price hit a new 52-week low during trading on Wednesday . The company traded as low as GBX 8.53 ($0.11) and last traded at GBX 8.53 ($0.11), with a volume of 153344 shares traded. The stock had previously closed at GBX 8.90 ($0.11).

Scancell Price Performance

The firm’s 50 day simple moving average is GBX 9.96 and its two-hundred day simple moving average is GBX 13.21. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The firm has a market capitalization of £88.35 million, a P/E ratio of -13.08 and a beta of 0.35.

Scancell (LON:SCLPGet Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share (EPS) for the quarter. As a group, analysts predict that Scancell Holdings plc will post -2.5361112 earnings per share for the current year.

Scancell Company Profile

(Get Free Report)

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

Recommended Stories

Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.